About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

No Difference in Death Rates Among Patients Exposed to Common Rheumatoid Arthritis Drugs: Study

by Rukmani Krishna on August 11, 2012 at 11:30 PM
Font : A-A+

 No Difference in Death Rates Among Patients Exposed to Common Rheumatoid Arthritis Drugs: Study

Confirmation was made by researchers that there was no significant difference in the rates of death among patients with rheumatoid arthritis (RA). The patients were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

RA is a chronic, autoimmune disease characterized by inflammation in the joints that causes pain, tenderness and swelling. The World Health Organization estimates that RA affects up to one percent of individuals worldwide, with more than one million Americans diagnosed with the disease according to the ACR. Rheumatologists recommend early intervention with biologic disease modifying anti-rheumatic drugs (DMARDs) such as TNF inhibitors to slow disease progression, improve function, and prevent disability.

Advertisement

In Sweden nearly 15% of RA patients are prescribed TNF inhibitors. The present study examined the mortality rates in RA patients exposed to adalimumab, etanercept, or infliximab. "Understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing RA," said lead author Dr. Julia Fridman Simard with the Clinical Epidemiology Unit at Karolinska Institute in Stockholm, Sweden.

Researchers linked data from the Swedish Biologics Register (ARTIS), a comprehensive database of patients initiating first-ever biologic therapy for rheumatic diseases, and information from national Swedish registers that included data such as all-cause mortality, demographics, and RA characteristics. Between 2003 and 2008, 1,609 patients with RA initiated treatment with adalimumab, 2,686 with etanercept, and 2,027 with infliximab as their first ever biologic DMARD.
Advertisement

There were more than 19,000 person-years of follow-up during the five-year study period during which time 211 patients died (3.3%). "While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with RA," concludes Dr. Simard.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Liver Transplantation
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Osteoarthritis Rheumatoid Arthritis Oligoarthritis Spondylolisthesis Chemotherapy Chemotherapy Drugs Death Facts Knee Replacement Reactive Arthritis Bereavement 

Most Popular on Medindia

Selfie Addiction Calculator How to Reduce School Bag Weight - Simple Tips The Essence of Yoga Indian Medical Journals Find a Doctor Nutam (400mg) (Piracetam) Post-Nasal Drip Turmeric Powder - Health Benefits, Uses & Side Effects Hearing Loss Calculator Find a Hospital
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use